FIELD: chemistry.
SUBSTANCE: present invention provides a dihydropyridazine-3,5-dione derivative or a pharmaceutically acceptable salt thereof, a prophylactic and / or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism and chronic renal failure, comprising the compound as an active ingredient.
EFFECT: present enables to solve problems that arise when using phosphorus adsorbents.
18 cl, 45 dwg, 418 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL AGENT CONTAINING INHIBITOR OF SODIUM-DEPENDENT PHOSPHATE CARRIER | 2015 |
|
RU2740008C2 |
PHARMACEUTICAL PRODUCT CONTAINING INHIBITOR OF SODIUM DEPENDENT PHOSPHATE CARRIER | 2015 |
|
RU2811864C1 |
THERAPEUTICALLY ACTIVE DERIVATIVES OF OXAZOLINE | 2013 |
|
RU2656209C2 |
N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDE COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | 2015 |
|
RU2821520C2 |
NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | 2017 |
|
RU2772283C2 |
NEW AZAQUINOLINE DERIVATIVES | 2018 |
|
RU2773290C2 |
HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | 2018 |
|
RU2797822C2 |
NOVEL PYRAZOLE PYRIMIDINE DERIVATIVES | 2017 |
|
RU2769448C2 |
PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS | 2009 |
|
RU2539568C2 |
1-[M-CARBOXAMIDO(HETERO)ARYL-METHYL]-HETEROCYCLYL-CARBOXAMIDE DERIVATIVES | 2013 |
|
RU2644761C2 |
Authors
Dates
2018-07-31—Published
2014-03-13—Filed